...
首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Obesity, non-alcoholic fatty liver disease, and atherothrombosis: A role for the intestinal microbiota?
【24h】

Obesity, non-alcoholic fatty liver disease, and atherothrombosis: A role for the intestinal microbiota?

机译:肥胖,非酒精性脂肪肝和动脉粥样硬化血栓形成:肠道菌群的作用?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Whereas the association between intestinal microorganisms and health has been widely accepted in the area of infectious disease, recent advances have now implied a role for the intestinal microbiota in human energy balance. In fact, numerous studies support an intricate relationship between the intestinal microbiota and obesity, as well as subsequent insulin resistance and non-alcoholic fatty liver disease. Intestinal microorganisms also seem to be involved in haemostatic tone and atherogenesis. However, as most of the findings stem from observational data, intervention studies in humans using interventions selectively aimed at altering the composition and activity of the intestinal microbiota are crucial to prove causality. If substantiated, this could open the arena for modulation of the intestinal microbiota as a future target in obesity-associated disease, both as a diagnostic test for personalized algorithms and for selective therapeutic strategies.
机译:尽管肠道微生物与健康之间的联系在传染病领域已被广泛接受,但目前的最新进展暗示了肠道菌群在人类能量平衡中的作用。事实上,许多研究支持肠道菌群与肥胖之间的复杂关系,以及随后的胰岛素抵抗和非酒精性脂肪肝疾病。肠道微生物似乎也参与了止血调和动脉粥样硬化的形成。但是,由于大多数发现均来自观察数据,因此采用选择性地改变肠道菌群组成和活性的干预措施对人体进行干预研究对于证明因果关系至关重要。如果得到证实,这可能为调节肠道菌群打开舞台,将其作为肥胖相关疾病的未来目标,既可以作为个性化算法的诊断测试,也可以作为选择性治疗策略的诊断手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号